文献速递慢性肾脏病水电解质与酸碱

尿毒症毒素硫酸吲哚酚通过调节铁调素干扰慢性肾脏病铁代谢

The uremic toxin indoxyl sulfate interferes with iron metabolism by regulating hepcidin in chronic kidney disease.
PubMed 文献 · Nephrol Dial Transplant · 2018-01-01

该研究探讨硫酸吲哚酚(IS)对慢性肾脏病(CKD)铁代谢的影响。体外实验用HepG2细胞,动物实验用腺嘌呤诱导的CKD小鼠,并设AST-120治疗组和IS饮水组。结果显示IS通过AhR和氧化应激途径上调铁调素,AST-120可改善CKD小鼠的铁代谢异常。

要点

  • IS通过AhR和氧化应激依赖途径上调肝细胞铁调素表达。
  • CKD小鼠铁调素升高、肾性贫血、血浆铁降低、铁蛋白升高、脾铁增加。
  • AST-120可降低CKD小鼠铁调素并改善铁代谢异常。

核心结论

  • IS通过AhR和氧化应激依赖途径参与铁调素调节,从而影响CKD铁代谢。

研究设计与样本

  • 体外实验使用HepG2细胞;动物实验使用腺嘌呤诱导的CKD小鼠模型。
  • CKD小鼠分为AST-120治疗组和未治疗组,另设对照小鼠和IS饮水处理小鼠。

主要发现

  • HepG2细胞中IS呈剂量依赖性增加铁调素表达。
  • 沉默AhR可抑制IS诱导的铁调素表达,抗氧化药物可减弱IS诱导的铁调素表达。
  • 腺嘌呤诱导CKD小鼠铁调素浓度升高,AST-120可降低该升高。
  • CKD小鼠表现肾性贫血、血浆铁降低、血浆铁蛋白升高、脾铁含量增加。
  • CKD小鼠十二指肠铁转运蛋白降低、脾铁转运蛋白升高,AST-120可改善这些改变。

临床怎么用

  • 在CKD铁代谢异常评估中,可关注尿毒症毒素IS对铁调素的调节作用。
  • 口服吸附剂AST-120可能通过降低IS改善CKD铁代谢紊乱。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hepcidin secreted by hepatocytes is a key regulator of iron metabolism throughout the body. Hepcidin concentrations are increased in chronic kidney disease (CKD), contributing to abnormalities in iron metabolism. Levels of indoxyl sulfate (IS), a uremic toxin, are also elevated in CKD. However, the effect of IS accumulation on iron metabolism remains unclear. METHODS: We used HepG2 cells to determine the mechanism by which IS regulates hepcidin concentrations. We also used a mouse model of adenine-induced CKD. The CKD mice were divided into two groups: one was treated using AST-120 and the other received no treatment. We examined control mice, CKD mice, CKD mice treated using AST-120 and mice treated with IS via drinking water. RESULTS: In the in vitro experiments using HepG2 cells, IS increased hepcidin expression in a dose-dependent manner. Silencing of the aryl hydrocarbon receptor (AhR) inhibited IS-induced hepcidin expression. Furthermore, IS induced oxidative stress and antioxidant drugs diminished IS-induced hepcidin expression. Adenine-induced CKD mice demonstrated an increase in hepcidin concentrations; this increase was reduced by AST-120, an oral adsorbent of the uremic toxin. CKD mice showed renal anemia, decreased plasma iron concentration, increased plasma ferritin and increased iron content in the spleen. Ferroportin was decreased in the duodenum and increased in the spleen. These changes were ameliorated by AST-120 treatment. Mice treated by direct IS administration showed hepatic hepcidin upregulation. CONCLUSIONS: IS affects iron metabolism in CKD by participating in hepcidin regulation via pathways that depend on AhR and oxidative stress.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Hamano H, Ikeda Y, Watanabe H, et al. The uremic toxin indoxyl sulfate interferes with iron metabolism by regulating hepcidin in chronic kidney disease. Nephrol Dial Transplant. 2018. PMID: 28992067. doi:10.1093/ndt/gfx252

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。